The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
Status:
Completed
Trial end date:
2017-08-06
Target enrollment:
Participant gender:
Summary
In this 5-year study, the investigators propose to evaluate the separate and combined effects
of the FDA-approved formulation of extended release naltrexone (Vivitrol®) and
employment-based reinforcement of opiate abstinence in promoting opiate abstinence and
reducing risky injection behavior in recently detoxified, opioid-dependent, injection drug
users.